| 翻訳と辞書 |
Baxalta
Baxalta (''Bax'', taken from its former parent company and ''Alta'' taken from the Latin ''Altus'' which translates as 'high' or 'profound'〔(【引用サイトリンク】title=An Error Occurred Setting Your User Cookie )〕) is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division.〔〔(【引用サイトリンク】title=Baxalta: Baxter's newly named biopharma spinout has had its ups and downs )〕 with revenue of $6 billion.
==Company History==
Baxalta inherited all of its parent company's on-the-market treatments, focused on hemophilia, The company aims to launch 20 in-development projects by 2020, heaping $2.5 billion in annual sales. Before being spun off, Baxalta acquired SuppreMol for $225 million. Baxalta also acquired the blockbuster leukemia drug Oncaspar from Sigma-Tau Finanziaria S.p.A. for $900 million.〔〔(【引用サイトリンク】title=Baxter Expands Cancer Therapies With $900M Oncaspar Buy )〕
In August 2015, Shire Plc made an unsolicited $30.6 billion stock offer for the company〔(【引用サイトリンク】title=Shire Offers $30B for Baxalta )〕 sending the Baxalta share price up over 16%. Baxalta investors would be set to receive 0.1687 of Shire's American Depositary Receipts for every share they hold, representing a premium of 36% when compared to the company's stock price as of August 3. This deal would also be set to create the largest global biotech company focused solely on rare diseases.〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Baxalta」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|